Abstract
Despite advances in medical and surgical therapy, cancer kills more than half a million people in the United States annually, and the majority of these patients succumb to metastatic disease. The traditional approach to treating systemic disease has been the use of cytotoxic chemotherapy. However, chemotherapy is rarely curative and toxicity is often dose limiting. In addition, the effects of chemotherapy are nonspecific, targeting both malignant and normal tissues. As a result, recent efforts increasingly have focused on developing agents that target specific molecules in tumor cells in order to both improve efficacy and limit toxicity. This review summarizes the history and current use of targeted molecular therapy for cancer, with a special emphasis on recently developed inhibitors of Focal Adhesion Kinase (FAK).
Keywords: Angiogenesis, carcinogenesis, focal adhesion kinase, targeted therapeutics, tyrosine kinase, Cancer, metastatic disease, cytotoxic chemotherapy, Tyrosine Kinase inhibitors, chronic myelogenous leukemia, RTK induces, CDK, Epidermal growth factor receptor, Vascular endothelial growth factor, flavopiridol
Anti-Cancer Agents in Medicinal Chemistry
Title: Evolving Therapies and FAK Inhibitors for the Treatment of Cancer
Volume: 10 Issue: 10
Author(s): Kelli Bullard Dunn, Melissa Heffler and Vita M. Golubovskaya
Affiliation:
Keywords: Angiogenesis, carcinogenesis, focal adhesion kinase, targeted therapeutics, tyrosine kinase, Cancer, metastatic disease, cytotoxic chemotherapy, Tyrosine Kinase inhibitors, chronic myelogenous leukemia, RTK induces, CDK, Epidermal growth factor receptor, Vascular endothelial growth factor, flavopiridol
Abstract: Despite advances in medical and surgical therapy, cancer kills more than half a million people in the United States annually, and the majority of these patients succumb to metastatic disease. The traditional approach to treating systemic disease has been the use of cytotoxic chemotherapy. However, chemotherapy is rarely curative and toxicity is often dose limiting. In addition, the effects of chemotherapy are nonspecific, targeting both malignant and normal tissues. As a result, recent efforts increasingly have focused on developing agents that target specific molecules in tumor cells in order to both improve efficacy and limit toxicity. This review summarizes the history and current use of targeted molecular therapy for cancer, with a special emphasis on recently developed inhibitors of Focal Adhesion Kinase (FAK).
Export Options
About this article
Cite this article as:
Bullard Dunn Kelli, Heffler Melissa and M. Golubovskaya Vita, Evolving Therapies and FAK Inhibitors for the Treatment of Cancer, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (10) . https://dx.doi.org/10.2174/187152010794728657
DOI https://dx.doi.org/10.2174/187152010794728657 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Modulation of Histone Acetylation by Garlic Sulfur Compounds
Anti-Cancer Agents in Medicinal Chemistry Synergistic Effect of Epidermal Growth Factor Receptor Inhibitors and Ionization Radiation in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Editorial (Thematic Issue: Current Research and Clinical Application in Head and Neck Radiotherapy)
Current Cancer Therapy Reviews Spectrum of Multimodality Findings in Post-surgical Breast Cancer Imaging
Current Medical Imaging Development and Application of Fourier-Transform Infrared Chemical Imaging of Tumour in Human Tissue
Current Medicinal Chemistry Ischemic Post-Conditioning Partially Reverses Cell Cycle Reactivity Following Ischemia/Reperfusion Injury: A Genome-Wide Survey
CNS & Neurological Disorders - Drug Targets Alzheimer’s Disease and Molecular Chaperones: Current Knowledge and the Future of Chaperonotherapy
Current Pharmaceutical Design Editorial [Hot Topic: Pancreatic Cancer: Between Bench and Bedside (Guest Editors: Davide Melisi and Alfredo Budillon)]
Current Drug Targets Ultrasonic and Microwave Assisted Synthesis of Nitrogen-Containing Derivatives of Juglone as Potential Antibacterial Agents
Letters in Organic Chemistry Natural Anti-Cancer Agents: Implications in Gemcitabine-Resistant Pancreatic Cancer Treatment
Mini-Reviews in Medicinal Chemistry Bone Target Radiotracers for Palliative Therapy of Bone Metastases
Current Medicinal Chemistry Non-Analgesic Effects of Opioids: Interactions Between Opioids and Other Drugs
Current Pharmaceutical Design Blockade of Furin Activity and Furin-Induced Tumor Cells Malignant Phenotypes By The Chemically Synthesized Human Furin Prodomain
Current Medicinal Chemistry Cucurbitacin B Enhances the Anticancer Effect of Imatinib Mesylate Through Inhibition of MMP-2 Expression in MCF-7 and SW480 Tumor Cell Lines
Anti-Cancer Agents in Medicinal Chemistry The Genomic Approaches to Major Depression
Current Pharmacogenomics In-silico Design, ADMET Screening, MM-GBSA Binding Free Energy of Some Novel Isoxazole Substituted 9-Anilinoacridines as HER2 Inhibitors Targeting Breast Cancer
Current Drug Research Reviews In Silico Modeling of Crabtree Effect
Endocrine, Metabolic & Immune Disorders - Drug Targets Glutathione Transferases as Targets for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Bioengineered 3D Scaffolds in Cancer Research: Focus on Epithelial to Mesenchymal Transition and Drug Screening
Current Pharmaceutical Design The Endothelin Axis as Therapeutic Target in Human Malignancies: Present and Future
Current Pharmaceutical Design